Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
Archives de Pédiatrie · 2024
DOI: 10.1016/j.arcped.2024.01.004 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Archives de Pédiatrie, 2024. Verfasst von Noel Peretti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospices Civil de Lyon, Pediatric Hospital Femme Mere Enfant HFME, Department of Pediatric Gastroenterology-Hepatology and Nutrition, Bron, France; L…. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Heterozygous familial hypercholesterolemia (HeFH) predisposes to premature cardiovascular diseases. Since 2015, the European Atherosclerosis Society has advocated initiation of statins at 8-10 years of age and a low-density lipoprotein cholesterol (LDL-C) target of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospices Civil de Lyon, Pediatric Hospital Femme Mere Enfant HFME, Department of Pediatric Gastroenterology-Hepatology and Nutrition, Bron, France; Lyon University, Claude Bernard Lyon-1 University, Lyon Est Medical Sch…
- Real World Evidence, Department of Public Health Expertise, Paris, France.
- CHU of Toulouse, Children Hospital, Department of pediatrics, Unit of Gastroenterology, Hepatology, Nutrition, and Inborn Errors of Metabolism, Toulouse, France; Toulouse University, Institute of Research in Digestive S…
- Assistance publique - Hôpitaux de Paris AP-HP, Trousseau Hospital, Department of Pediatric Nutrition and Gastroenterology, Paris, France.
- Assistance publique - Hôpitaux de Marseille AP-HM, Timone Children's Hospital, Pediatric Multidisciplinary Unit, Marseille, France.
- Assistance publique - Hôpitaux de Paris AP-HP, Trousseau Hospital, Department of Pediatric Nutrition and Gastroenterology, Paris, France; Sorbonne University, Paris, France.
Zitieren
APA
Peretti, N., Vimont, A., Mas, E., Lemale, J., Reynaud, R., Tounian, P., Poinsot, P., Restier, L., Paillard, F., Pradignac, A., Pucheu, Y., Rabès, J. P., Bruckert, E., Gallo, A., & Béliard, S. (2024). Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort. Archives de Pédiatrie. https://doi.org/10.1016/j.arcped.2024.01.004
Vancouver
Peretti N, Vimont A, Mas E, Lemale J, Reynaud R, Tounian P, et al. Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort. Archives de Pédiatrie. 2024. doi:10.1016/j.arcped.2024.01.004
BibTeX
@article{Peretti2024,
author = {Peretti, Noel and Vimont, Alexandre and Mas, Emmanuel and Lemale, Julie and Reynaud, Rachel and Tounian, Patrick and Poinsot, Pierre and Restier, Liora and Paillard, François and Pradignac, Alain and Pucheu, Yann and Rabès, Jean-Pierre and Bruckert, Eric and Gallo, Antonio and Béliard, Sophie},
title = {Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort},
journal = {Archives de Pédiatrie},
year = {2024},
doi = {10.1016/j.arcped.2024.01.004}
}
EUVIMED